A PBPK Workflow for First-in-human Dose Selection of a Subcutaneously Administered Pegylated Peptide

Overview

Journal J Pharmacokinet Pharmacodyn

Publisher Springer

Specialty Pharmacology

Date 2015 Feb 5

PMID 25650156

Citations 9

Authors

Elliot Offman

Andrea N Edginton

Affiliations

Soon will be listed here.

Abstract

Predicting the pharmacokinetic (PK) time course of a subcutaneously (SC) administered novel therapeutic protein using in silico approaches offers an opportunity to streamline the drug development process by facilitating selection of starting and target doses in initial human trials. Herein, we propose a workflow for predicting the human exposure time course following SC administration. Leveraging knowledge obtained following both intravenous and SC administration in monkeys, this workflow employs the development of a whole body physiologically-based pharmacokinetic (PBPK) model incorporating vascular circulation, lymphatic uptake and both renal and non-specific clearance mechanisms to predict the PK of a novel pegylated peptide. Optimization of the model was initially performed in monkeys, after which the model was scaled up to human proportion. Inclusion of a SC depot compartment allowed for precise simulation of the SC time course in monkeys. Simulated human exposure after SC administration was within approximately 20 % of the observed values and successfully predicted the time course of two subsequent dosing levels. This workflow represents one of the first publications of a PBPK workflow to predict the time course of a SC administered therapeutic protein based off of a single, non-human primate species and shows promise in facilitating the dose selection in first-in-human dose escalation studies for novel protein therapeutics.

Citing Articles

Utilization of Physiologically Based Pharmacokinetic Modeling in Pharmacokinetic Study of Natural Medicine: An Overview.

Jia Q, He Q, Yao L, Li M, Lin J, Tang Z Molecules. 2022; 27(24).

PMID: 36557804 PMC: 9782767. DOI: 10.3390/molecules27248670.

Monoclonal Antibody Pharmacokinetics in Cynomolgus Monkeys Following Subcutaneous Administration: Physiologically Based Model Predictions from Physiochemical Properties.

Hu S, Datta-Mannan A, DArgenio D AAPS J. 2022; 25(1):5.

PMID: 36456779 DOI: 10.1208/s12248-022-00772-4.

Mathematical Models to Characterize the Absorption, Distribution, Metabolism, and Excretion of Protein Therapeutics.

Liu S, Shah D Drug Metab Dispos. 2022; 50(6):867-878.

PMID: 35197311 PMC: 11022906. DOI: 10.1124/dmd.121.000460.

Current and prospective computational approaches and challenges for developing COVID-19 vaccines.

Hwang W, Lei W, Katritsis N, MacMahon M, Chapman K, Han N Adv Drug Deliv Rev. 2021; 172:249-274.

PMID: 33561453 PMC: 7871111. DOI: 10.1016/j.addr.2021.02.004.

Sampling Site Has a Critical Impact on Physiologically Based Pharmacokinetic Modeling.

Huang W, Isoherranen N J Pharmacol Exp Ther. 2019; 372(1):30-45.

PMID: 31604807 PMC: 6904886. DOI: 10.1124/jpet.119.262154.

References

Ling J, Zhou H, Jiao Q, Davis H . Interspecies scaling of therapeutic monoclonal antibodies: initial look. J Clin Pharmacol. 2009; 49(12):1382-402. DOI: 10.1177/0091270009337134. View

Baumann A, Tuerck D, Prabhu S, Dickmann L, Sims J . Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis?. Drug Discov Today. 2014; 19(10):1623-31. DOI: 10.1016/j.drudis.2014.06.002. View

Dong J, Salinger D, Endres C, Gibbs J, Hsu C, Stouch B . Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet. 2011; 50(2):131-42. DOI: 10.2165/11537430-000000000-00000. View

Shah D, Betts A . Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2011; 39(1):67-86. DOI: 10.1007/s10928-011-9232-2. View

Offman E, Edginton A . Contrasting toxicokinetic evaluations and interspecies pharmacokinetic scaling approaches for small molecules and biologics: applicability to biosimilar development. Xenobiotica. 2012; 43(6):561-9. DOI: 10.3109/00498254.2012.744113. View

Garg A, Balthasar J . Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn. 2007; 34(5):687-709. DOI: 10.1007/s10928-007-9065-1. View

Sarin H . Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res. 2010; 2:14. PMC: 2928191. DOI: 10.1186/2040-2384-2-14. View

Rippe B, Haraldsson B . Fluid and protein fluxes across small and large pores in the microvasculature. Application of two-pore equations. Acta Physiol Scand. 1987; 131(3):411-28. DOI: 10.1111/j.1748-1716.1987.tb08257.x. View

Dahlberg A, Kaminskas L, Smith A, Nicolazzo J, Porter C, Bulitta J . The lymphatic system plays a major role in the intravenous and subcutaneous pharmacokinetics of trastuzumab in rats. Mol Pharm. 2013; 11(2):496-504. DOI: 10.1021/mp400464s. View

10.

Rippe B, Haraldsson B . Transport of macromolecules across microvascular walls: the two-pore theory. Physiol Rev. 1994; 74(1):163-219. DOI: 10.1152/physrev.1994.74.1.163. View

11.

Li Z, Rana T . Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov. 2014; 13(8):622-38. DOI: 10.1038/nrd4359. View

12.

Ferl G, Wu A, DiStefano 3rd J . A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng. 2005; 33(11):1640-52. DOI: 10.1007/s10439-005-7410-3. View

13.

Davies B, Morris T . Physiological parameters in laboratory animals and humans. Pharm Res. 1993; 10(7):1093-5. DOI: 10.1023/a:1018943613122. View

14.

Zhao L, Ji P, Li Z, Roy P, Sahajwalla C . The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model. J Clin Pharmacol. 2013; 53(3):314-25. DOI: 10.1002/jcph.4. View

15.

Zheng Y, Tesar D, Benincosa L, Birnbock H, Boswell C, Bumbaca D . Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration. MAbs. 2012; 4(2):243-55. PMC: 3361660. DOI: 10.4161/mabs.4.2.19387. View

16.

Deng R, Iyer S, Theil F, Mortensen D, Fielder P, Prabhu S . Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?. MAbs. 2010; 3(1):61-6. PMC: 3038012. DOI: 10.4161/mabs.3.1.13799. View

17.

Swartz M . The physiology of the lymphatic system. Adv Drug Deliv Rev. 2001; 50(1-2):3-20. DOI: 10.1016/s0169-409x(01)00150-8. View

18.

Wang W, Chen N, Shen X, Cunningham P, Fauty S, Michel K . Lymphatic transport and catabolism of therapeutic proteins after subcutaneous administration to rats and dogs. Drug Metab Dispos. 2012; 40(5):952-62. DOI: 10.1124/dmd.111.043604. View

19.

Kagan L, Mager D . Mechanisms of subcutaneous absorption of rituximab in rats. Drug Metab Dispos. 2012; 41(1):248-55. DOI: 10.1124/dmd.112.048496. View

20.

Graf J, Scholz B, Zavodszky M . BioDMET: a physiologically based pharmacokinetic simulation tool for assessing proposed solutions to complex biological problems. J Pharmacokinet Pharmacodyn. 2011; 39(1):37-54. PMC: 3258408. DOI: 10.1007/s10928-011-9229-x. View